Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.0002
Latest analyst grade actions
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.52 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 50.00 | Oscillator | Neutral |
| Williams %R (14) | -50.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.00 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 28.28 (+DI 10.7 / -DI 16.3) | Trend |
| EMA 20 | 0.00 | MA | Strong Sell |
| SMA 20 | 0.00 | MA | Strong Sell |
| EMA 50 | 0.00 | MA | Strong Sell |
| SMA 50 | 0.00 | MA | Strong Sell |
| SMA 200 | 0.00 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 5, 25 | Balencic Jordan Paul | 10 percent owner, officer: Chief Executive Officer | 0 | — | |
| Sep 5, 25 | Balencic Jordan Paul | 10 percent owner, officer: Chief Executive Officer | 0 | — |
Stock news · updated daily
Strategic transaction aligns NXTN and BFCH around a separately traded wellness platform combining operating assets, experienced leadership and multiple ave
Transaction is structured around a negotiated $0.0004 per-share BFCH reference value and is intended to establish a controlled public health, wellness, longevity and human-optimization platform Transaction is structured around a negotiated $0.0004 per-share BFCH reference value and is intended to establish a controlled public health, wellness, longevity and human-optimization platform
Reported EPS vs. consensus estimate
TTM vs. 5-year historical average (annual ratios)
| Metric | BFCH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.6x | 7.1x · sector 38.2x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 0.4x | -31.0x | Discount |
| Price / Sales | 9.3x | 4.4x | Elevated |
| EV / EBITDA | -2.3x | -48.8x | Discount |
| Return on equity | 462.5% | — | Top tier |
| Gross margin | -119.9% | 23.3% | Below hist. |
| Debt / Equity | 0.41 | -7.13 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -8.40 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 253G1 | Aug 14, 2026 | 2026-08-14 09:18:29 | View |
| QUALIF | Aug 13, 2026 | 2026-08-14 00:15:04 | View |
| 1-A POS | Aug 3, 2026 | 2026-08-03 13:06:42 | View |
| 253G2 | Jul 24, 2026 | 2026-07-24 14:55:51 | View |
| 253G1 | Jul 24, 2026 | 2026-07-24 14:01:50 | View |
| QUALIF | Jul 23, 2026 | 2026-07-24 00:15:08 | View |
| 1-A | Jul 9, 2026 | 2026-07-08 18:27:23 | View |
Proxy statement (DEF 14A) disclosures